PRIVACY POLICY

Incyte processes personal data about you such as your name, business contact information, and practice area in order to communicate with you about cholangiocarcinoma disease education, and if you opt in to the additional uses of your personal data for the purposes described below.

Depending on your location, you may have the right to access, delete, restrict, edit, move, or object to the use of your personal data. You also may have a right to report concerns to the authority responsible for data privacy where you live or work, depending on your location.

You can learn more about Incyte’s data protection practices here. By accessing this link you can learn about the types of personal data we collect, how we use it, whether collection and processing is optional, sources of the personal data we process, how it is shared, where it is stored or transferred to, how long we keep it, and contact information for Incyte, Incyte’s data protection officer, and your supervisory authority.

Please contact privacy@incyte.com if you have any questions or concerns or would like to exercise your rights.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events in the UK should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Incyte by calling 00‑800‑0002‑7423

Adverse events in ROI should be reported.

Reporting forms and information can be found at HPRA Pharmacovigilance: www.hpra.ie

Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800456748

EXTERNAL LINK DISCLAIMER

CAUTION

An error occured

PRIVACY POLICY